glp 1 in spain Weight-Loss Medications Are Effective for Reducing Body Weight, but Long-Term Data and Independent Studies Are Still Lacking AEMPS Provides Update on GLP-1
Description
Metabolic changes In a double-blind, placebo-controlled RCT conducted by Frssing et al
Ding WG, Gromada J

As the popularity of GLP-1 receptor agonists such as Ozempic, Wegovy, and Zepbound increases, a newly reported complication known as Ozempic feet has become a growing concern

Liu C, Li C, Cai X, Zou Y, Mo J, Chen B, et al
SheMed is monitoring its development closely and will update guidance as the regulatory picture becomes clearer

doi: 10.1056/NEJM197409122911102